GeneDx Holdings Corp. (Nasdaq: WGS) announced a leadership transition on November 15, 2026, appointing Everett Cunningham as Chief Executive Officer. The appointment is effective on or before December 15, 2026, coinciding with the departure of current CEO Katherine Stueland.
Ms. Stueland will step down as CEO and resign from the Board of Directors effective the Transition Date. Her departure is not related to any disagreements regarding the company's operations. She will remain with GeneDx as an Executive Advisor, reporting to the Board, through January 31, 2027.
Mr. Cunningham joins GeneDx from Quanterix Corporation, where he served as President and CEO from January 2026 to November 2026. His prior experience includes serving as Chief Commercial Officer at Illumina (June 2024 to January 2026) and Exact Sciences (2021 to 2024). He also previously held leadership roles at GE Healthcare, Quest Diagnostics, and Pfizer. Mr. Cunningham will also serve as a Class II director on the Board, with a term expiring at the company's 2029 annual meeting of stockholders.
In connection with his appointment, Mr. Cunningham will receive an initial annual base salary of $750,000 and a target annual cash bonus equal to 100% of his base salary, with the actual bonus ranging from 0% to 150% of the target, beginning in fiscal year 2027. He is also eligible for a sign-on cash bonus of $1,050,000, subject to repayment under specific termination circumstances. Additionally, on the Grant Date, Mr. Cunningham will be granted a restricted stock unit award valued at $10.0 million and a performance-based restricted stock unit award valued at $10.0 million, both based on a 60-trading-day trailing average closing price.
Regarding compensation for Ms. Stueland's departure, the company entered into a transition agreement. In lieu of salary severance, she will receive accelerated vesting of restricted stock units that would have vested in March 2027. She will also continue to receive her current compensation and vest in outstanding equity awards through January 31, 2027.
GeneDx reaffirmed its full year 2026 financial guidance, as provided on November 9, 2026, in connection with the release of its third quarter 2026 financial results.